Latest Genmab Stories

Second Janssen oncology compound to receive Breakthrough Therapy Designation RARITAN, N.J., May 1, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double...

NEW YORK, LONDON, BERLIN, PARIS, March 19, 2013 /PRNewswire/ -- The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market [http://www.reportstack.com/product/99233/monoclonal-antibodies-market-in-rheumatoid-arthritis-to-2018-market-characterized-by-large-and-diversified-pipeline-and-low-threat-of-biosimilar-sales-erosion.html ] , constituting four of the global top 20 best-selling drugs. The...

CHICAGO, Sept. 4, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS), GlaxoSmithKline (NYSE:GSK), Monsanto Company (NYSE:MON) and Syngenta AG (NYSE:SYT). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get the...

THOUSAND OAKS, Calif. and LONDON, April 2, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)). The companies believe all the molecules have novel profiles and offer the potential to deliver important treatments across multiple indications in inflammatory diseases. The...

DALLAS, December 8, 2011 /PRNewswire/ -- The report "Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in geographies such as North America, Europe, and Japan. Browse market data tables and in-depth TOC on "Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)"....

DALLAS, Texas, November 21, 2011 /PRNewswire/ -- The report "Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in North America, & Europe. Browse market data tables and in-depth TOC on Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic...

MONROVIA, Calif., Oct. 21, 2011 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb®5871, the company's therapeutic antibody for the treatment of autoimmune diseases. XmAb5871 uses a novel dual-targeted approach to potently suppress autoimmune disorders that may avoid some of the side effects seen with other...

BOTHELL, Wash., June 20, 2011 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced it will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2b clinical trial in rheumatoid arthritis for ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6). The milestone payment is part of the Alder/Bristol-Myers Squibb collaboration that was formed in 2009 for the development of ALD518/BMS-945429. Under the...

THOUSAND OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb(®)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases. Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Phase 2...

ORLANDO, Fla., Dec. 7, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer (NSCLC). After 12 weeks of treatment with the anti-inflammatory therapeutic, 58 percent of patients who received ALD518 experienced hemoglobin level increases from less than 11 g/dL to more than 12 g/dL,...